Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation

What Was Tested

This randomized controlled trial paper looks at GIP (Gastric Inhibitory Polypeptide).

This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation.

Who Took Part

According to the abstract, 2 subjects were involved.

The age groups tagged for this paper are middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got GIP (Gastric Inhibitory Polypeptide) and who got the comparison, which limits bias.

Each person switched between GIP (Gastric Inhibitory Polypeptide) and the comparison at some point, usually with a gap in between.

What Was Measured

This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation.

PubMed files the paper under topics including Adamantane, Cyclohexanes, Diabetes Mellitus, Type 2, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Gastric Inhibitory Polypeptide and Insulin.

What This Means in Plain Language

The paper is a randomized and crossover study of GIP (Gastric Inhibitory Polypeptide) in 2 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (European journal of endocrinology), a journal based in England.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.